Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(7 years ago) | |
US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(8 months ago) | |
US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(2 years from now) | |
US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-268) | Jun 29, 2025 |
New Indication(I-785) | Jun 29, 2021 |
Orphan Drug Exclusivity(ODE) | Dec 15, 2021 |
New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
New Product(NP) | Dec 15, 2017 |
Orphan Drug Exclusivity(ODE-81) | Dec 15, 2021 |
NCE-1 date: 14 December, 2016
Market Authorisation Date: 29 June, 2018
Treatment: Method of treating acromegaly; Method of treating disorders with an etiology comprising or associated with excess gh-secretion
Dosage: FOR SUSPENSION;INTRAMUSCULAR